Important note: Information in this article was accurate in 2006. The state of the art may have changed since the publication date.
Los Angeles Times - July 17, 2006
Today, many developing countries impose tariffs on medicines and medical devices. Zimbabwe and the Democratic Republic of Congo, for instance, impose tariffs of about 8%. Others, such as India and Morocco, impose levies double that. Ironically, these nations gain relatively little revenue from such taxes; according to one survey, money from tariffs on medicines usually accounts for less than 0.5% of total government revenue. This is one reason that a third of the world's population lacks adequate medical care and has low life expectancy and high rates of disease.
The United States, Switzerland and Singapore have proposed removing import tariffs on medicines in the current round of trade talks that began in 2001 in Doha, Qatar. But the talks have repeatedly stalled, mostly because wealthy countries, such as the U.S. and several in Europe, refuse to end their indefensible agriculture subsidies. Reducing farm subsidies would help rich and poor nations alike. But there are other benefits the trade deal could bring. There's plenty of evidence, for example, to show that reducing tariffs on medicine and other health-related products produces abundant rewards.
In 2000, several African countries promised to reduce taxes on bed nets, which block mosquitoes and help lower malarial infections. As a result, in several countries that have dropped the duties, the cost of bed nets has fallen by 50%, sales have soared and malarial rates appear to be falling. Imagine what could happen if more of the world could afford antibiotics, vaccines and HIV drugs.
Opening more of the world's markets would no doubt benefit countries with large pharmaceutical industries, which include the U.S., Switzerland and Singapore. That's been a sore point for many trade ministers. But if companies in those countries benefit from an increase in sales, people who now can't afford the drugs would benefit even more.
060717
LT060710
Copyright © 2006 - Los Angeles Times. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Los Angeles Times, Permissions, Times Mirror Square, Los Angeles, CA 90053. http://www.latimes.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 2006. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2006. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .